Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Receivables - Other (2020 - 2024)

Historic Receivables - Other for Heron Therapeutics (HRTX) over the last 5 years, with Q4 2024 value amounting to $263000.0.

  • Heron Therapeutics' Receivables - Other fell 1516.13% to $263000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $263000.0, marking a year-over-year decrease of 1516.13%. This contributed to the annual value of $263000.0 for FY2024, which is 1516.13% down from last year.
  • Heron Therapeutics' Receivables - Other amounted to $263000.0 in Q4 2024, which was down 1516.13% from $310000.0 recorded in Q4 2023.
  • Heron Therapeutics' 5-year Receivables - Other high stood at $6.2 million for Q4 2022, and its period low was $245000.0 during Q4 2021.
  • Over the past 5 years, Heron Therapeutics' median Receivables - Other value was $310000.0 (recorded in 2023), while the average stood at $1.5 million.
  • Per our database at Business Quant, Heron Therapeutics' Receivables - Other skyrocketed by 242938.78% in 2022 and then tumbled by 9499.76% in 2023.
  • Quarter analysis of 5 years shows Heron Therapeutics' Receivables - Other stood at $334000.0 in 2020, then dropped by 26.65% to $245000.0 in 2021, then soared by 2429.39% to $6.2 million in 2022, then crashed by 95.0% to $310000.0 in 2023, then decreased by 15.16% to $263000.0 in 2024.
  • Its Receivables - Other stands at $263000.0 for Q4 2024, versus $310000.0 for Q4 2023 and $6.2 million for Q4 2022.